Pacira BioSciences announced that the U.S. District Court for the District of New Jersey has found that the company’s U.S. Patent No. 11,033,495, or “the ‘495 patent,” is not valid. “We remain steadfast in our belief in the strength and validity of our intellectual property and that eVenus is infringing upon our patents. In light of the Court’s decision, we are considering our legal options, which include pursuing an appellate review at the U.S. Court of Appeals for the Federal Court as warranted. We firmly believe we have built a strong portfolio of intellectual property and that the EXPAREL franchise is well protected on multiple levels. Three separate infringement suits are underway, and we have additional patents that are forthcoming,” said Frank Lee, Chief Executive Officer of Pacira BioSciences.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
- Pacira price target lowered to $37 from $41 at Raymond James
- Pacira price target lowered to $37 from $42 at RBC Capital
- Pacira backs FY24 revenue view $680M-$705M, consensus $694.66M
- Pacira reports Q2 EPS 89c, consensus 70c